ACADIA Pharmaceuticals ACAD has been analyzed by 25 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 13 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 4 | 7 | 3 | 0 | 0 |
| 3M Ago | 3 | 4 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $32.93, a high estimate of $42.00, and a low estimate of $19.00. Experiencing a 10.08% decline, the current average is now lower than the previous average price target of $36.62.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of ACADIA Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $37.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $37.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $32.00 | - |
| Tessa Romero | JP Morgan | Lowers | Overweight | $25.00 | $29.00 |
| Jeffrey Hung | Morgan Stanley | Lowers | Overweight | $30.00 | $40.00 |
| David Hoang | Citigroup | Lowers | Buy | $30.19 | $38.00 |
| Gregory Renza | RBC Capital | Lowers | Outperform | $30.00 | $35.00 |
| Uy Ear | Mizuho | Lowers | Neutral | $25.00 | $39.00 |
| Jason Butler | JMP Securities | Lowers | Outperform | $39.00 | $44.00 |
| Charles Duncan | Cantor Fitzgerald | Lowers | Overweight | $37.00 | $42.00 |
| Joel Beatty | Baird | Lowers | Outperform | $31.00 | $40.00 |
| Jay Olson | Oppenheimer | Lowers | Perform | $19.00 | $25.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Neutral | $30.00 | $33.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $33.00 | $40.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $33.00 | - |
| Ami Fadia | Needham | Lowers | Buy | $32.00 | $36.00 |
| Tessa Romero | JP Morgan | Lowers | Overweight | $29.00 | $32.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $33.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $42.00 | - |
| Gregory Renza | RBC Capital | Lowers | Outperform | $35.00 | $36.00 |
| Uy Ear | Mizuho | Lowers | Buy | $39.00 | $40.00 |
| Ami Fadia | Needham | Lowers | Buy | $36.00 | $37.00 |
| Jason Butler | JMP Securities | Maintains | Market Outperform | $42.00 | - |
| Jay Olson | Oppenheimer | Maintains | Perform | $25.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $42.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACADIA Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ACADIA Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on ACADIA Pharmaceuticals analyst ratings.
Discovering ACADIA Pharmaceuticals: A Closer Look
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
A Deep Dive into ACADIA Pharmaceuticals's Financials
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 69.27%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: ACADIA Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 19.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 11.54%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ACADIA Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 6.63%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.
Analyst Ratings: What Are They?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
